Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesClinical Nephrology
You have accessRestricted Access

The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies

Richard Fish, Jennifer Pinney, Poorva Jain, Clara Addison, Chris Jones, Satish Jayawardene, John Booth, Alexander J. Howie, Tareck Ghonemy, Shahista Rajabali, David Roberts, Lucy White, Sofia Khan, Matthew Morgan, Paul Cockwell and Colin A. Hutchison
CJASN November 2010, 5 (11) 1977-1980; DOI: https://doi.org/10.2215/CJN.00650110
Richard Fish
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Pinney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poorva Jain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara Addison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satish Jayawardene
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Booth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander J. Howie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tareck Ghonemy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahista Rajabali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Roberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy White
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Khan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Morgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Cockwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin A. Hutchison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives: Monoclonal gammopathies frequently cause renal disease, but they may be an incidental finding. Assessment of renal pathology in the context of renal dysfunction and a monoclonal gammopathy therefore serves as a useful diagnostic tool and, in addition, provides prognostic information. There is, however, a theoretical risk of increased hemorrhagic complications from renal biopsies in this setting. The purpose of this study was to determine the incidence of significant hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.

Design, setting, participants, & measurements: The case notes of 1993 unselected patients from four teaching hospitals within the United Kingdom who underwent native or transplant renal biopsies between 1993 and 2008 were reviewed. Subjects were categorized as having a monoclonal gammopathy or not, and the incidence of major hemorrhagic complications between groups was compared.

Results: In total, 74 (3.7%) patients (native and transplant biopsies) had a major hemorrhagic complication. One hundred forty-eight subjects with a monoclonal gammopathy were identified. The complication rate in this group was 4.1% compared with 3.9% in the control population (native biopsies only; P = 0.88).

Conclusions: In the population studied, the rate of major hemorrhagic complications after percutaneous renal biopsy was not significantly greater in patients with a monoclonal gammopathy.

Paraproteins are frequently detected in patients with renal disease, both as an incidental finding and as the underlying cause of the renal injury. The renal disorders associated with paraproteins are well described (1,2). In the context of severe acute kidney injury, cast nephropathy (myeloma kidney) is the most frequent finding (2,3). In contrast, patients presenting with heavy proteinuria and milder renal impairment are more likely to have amyloidosis (2,4) or light chain deposition disease (2,5). The conclusion that the presence of a paraprotein in the context of renal injury equates to a causal association cannot be drawn because of the high frequency of incidental paraproteins in this setting (6). For this reason, assessment of renal pathology is essential. In addition to confirming the underlying disorder and therefore allowing the initiation of disease specific treatment, pathologic features are also prognostic of clinical outcomes (2,5,7).

Despite these advantages, many clinicians are reluctant to perform percutaneous renal biopsies in patients with paraproteins because of the theoretical risk of a higher rate of hemorrhagic complications (8,9). Indeed, there are a number of mechanisms by which paraproteins might confer this increased risk (10,11). Therefore, renal histology has not been used as an inclusion criterion for some studies that have investigated the optimal treatment strategies for paraprotein-related renal disease (9). In turn, this makes interpretation of the results of these studies difficult (12–14). However, clear evidence that performing percutaneous renal biopsies in these patients is associated with an actual higher incidence of clinically significant hemorrhagic complications is not well reported. In fact, recent work has implied that the procedure is relatively safe in patients with amyloidosis, traditionally the subgroup considered to be most at risk (15). The purpose of this study was to determine the incidence of major hemorrhagic complications after percutaneous renal biopsies in a large population of patients with monoclonal gammopathies.

Materials and Methods

The electronic databases from four large teaching hospitals within the United Kingdom, University Hospital Birmingham, Birmingham; The Royal Free Hospital, London; The Royal London Hospital, London; and King's College Hospital, London, were searched to identify an unselected population of patients with both renal impairment and a monoclonal gammopathy in whom a renal biopsy was undertaken. Renal impairment was defined as being present if at least one of the following criteria were met: an estimated GFR of <60 ml/min (using the Modification of Diet in Renal Disease equation) (16) or proteinuria of >0.5 g/24 h as estimated by either a spot urine protein-to-creatinine ratio or a 24-hour urine collection. A comparative control population was also identified from the same units.

Retrospective analysis of the patients' records was undertaken to determine the incidence of significant hemorrhagic complications after renal biopsy. These were defined as a confirmed hematoma (hemorrhage) on radiologic imaging (ultrasound or computer tomography) or documented macroscopic hematuria. Radiologic imaging was only performed in those cases where the clinical picture was suspicious for bleeding postprocedure, i.e., patients who became hemodynamically unstable, had significant pain, or had persistent significant hematuria. Hemoglobin was not routinely measured postprocedure. Rates of radiologic and surgical interventions were also collected.

The percutaneous renal biopsies were undertaken using real-time ultrasound imaging using spring-loaded automated devices. Local protocols were adhered to regarding prebiopsy screening of hematologic parameters, BP, and kidney size. Briefly, correction of hematologic parameters was required prebiopsy if platelets were <100 × 109/L and/or the international normalized ratio was >1.4. Biopsies were not performed if prebiopsy ultrasound scanning showed evidence of obstruction or kidney sizes of <8 cm bilaterally. A biopsy was not performed if prebiopsy BP exceeded 160 mmHg systolic or 90 mmHg diastolic.

Patients with renal disease secondary to monoclonal gammopathies were defined as a histologic diagnosis of myeloma kidney (cast nephropathy), amyloid, and monoclonal free light chain deposition (light chain deposition disease or crystal deposits within the tubules). Patient variables and rates of hemorrhagic complications were compared between study groups using a t test and the χ2, as appropriate (SPSS 14.0; SPSS, Chicago, IL). Values of P < 0.05 were considered statistically significant.

Results

The outcomes for 1993 patients who underwent renal biopsies between January 1993 and December 2008 were reviewed. A total of 1193 native and 800 transplant biopsies were performed (Table 1). In total, 74 patients had a significant hemorrhagic complication (3.7%). Of these, 64 had macroscopic hematuria (3.2%), 15 had a confirmed radiologic hematoma (0.7%), and 5 required radiologic intervention (0.3%). No patients required surgical intervention or died as a result of the renal biopsy. Seven patients required a blood transfusion, and of the 64 patients where data were available, 39 had an indwelling urinary catheter placed.

View this table:
  • View inline
  • View popup
Table 1.

Population demographics

The risk of a hemorrhagic complication was not associated with the patients' age (48 ± 15 versus 55 ± 17 [SD] years in the patients with and without complications, respectively; P = 0.13) or degree of renal dysfunction (serum creatinine 3.15 ± 2.38 versus 3.24 ± 2.59 mg/dl, respectively; P = 0.81). Nor was there a significant difference in the rate of complications between patients undergoing native and transplant renal biopsies (4.0 and 3.3%, respectively; P = 0.4).

One hundred thirty-eight patients were identified to have a histologic lesion associated with a monoclonal gammopathy (Table 2). In addition, a further 10 patients were known to have multiple myeloma but did not have histologic evidence of a monoclonal process. One biopsy was of a renal transplant in this population; the remainder were native. In total, 4.1% of the 147 patients with a monoclonal gammopathy undergoing a native renal biopsy had a significant hemorrhagic complication. This was not significantly greater than those patients without a monoclonal gammopathy undergoing native biopsies (3.9%, P = 0.88). The rate of complications in patients undergoing native renal biopsies with biopsy-proven monoclonal renal disease was 4.4%, which was not significantly higher than those without monoclonal gammopathies (3.9%, P = 0.67). Thirty-five patients had a renal diagnosis of amyloid. None of these had a significant hemorrhagic episode. In comparison, 6.5% of the 92 patients with cast nephropathy did have a significant bleeding episode (P = 0.12; Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Renal findings in patients with monoclonal gammopathies and associated hemorrhagic complications

Discussion

The overall rate of clinically significant hemorrhagic complications in this study was 3.7%. This is comparable to previous work, where major hemorrhagic complication rates after native renal biopsies were reported as ranging from 1 to 8% (15,17–21). This study included 148 patients with a known monoclonal gammopathy. Major hemorrhagic complications occurred in 4.0% of these cases. This was not significantly greater than the incidence in patients without monoclonal gammopathies undergoing native renal biopsies (3.9%).

Numerous studies have investigated the potential risk factors for complications after percutaneous renal biopsy (17–20). Although monoclonal gammopathy–associated disease has been suggested to confer an increased risk of hemorrhagic complications (8,9), the current evidence supporting this theory is sparse. Moreover, a recent study to investigate the use of plasma exchange in treating cast nephropathy reported no complications after renal biopsies in 28 patients with myeloma (12). To date, there has not been a study specifically designed to examine the hemorrhagic complication rate of biopsies performed in patients with monoclonal gammopathies. A few studies have analyzed the bleeding risk associated specifically with amyloidosis. Eiro et al. (20) found a higher rate of bleeding (defined as drop in hemoglobin by >1 g/dl) in patients with amyloidosis compared with other histologic findings, although this considered just four patients with the diagnosis. Conversely, Soares et al. (15) found 4% of 101 patients with amyloidosis developed a major hemorrhagic complication; this was not significantly greater than the control group. This study included 35 patients with amyloidosis. None of these had a significant hemorrhagic complication.

The six major hemorrhagic complications seen in patients with monoclonal gammopathies in this study all occurred in patients with cast nephropathy. This presumably reflects the clinical context, acute kidney injury, in which a diagnosis of cast nephropathy will be made. Potentially, however, this could also relate to the higher serum concentrations of monoclonal free light chains likely to have been present in these patients (22). Coating of platelets with free light chains is one recognized mechanism by which patients with monoclonal gammopathies have an increased bleeding risk (10). Other more common mechanisms, in this context, include thrombocytopenia caused by bone marrow infiltration and clotting defects caused by sepsis and uremia. Less common hematologic irregularities arising in association with paraproteins include heparin-like circulating anticoagulants, factor X deficiency, endothelial interference, in cases of amyloidosis, and acquired von Willebrand syndrome (10,11). A number of these conditions will result in abnormal coagulation profiles, although some will be more difficult to detect. The protocols used by the institutes in this study included routine prebiopsy screening for impairment of clotting. Procedures were not performed if these parameters were outside the accepted reference ranges. The results suggest that, when this approach is followed, renal biopsies can be undertaken safely in these patients. This observation is particularly important in the context of considering new invasive treatment options (23,24).

In our 148 patients with a renal injury and a known paraproteinemia, by far the most common histologic diagnosis was cast nephropathy, which was found in 62% of cases. This was followed by amyloidosis at 23%. Additionally, a further 3.4% of biopsies showed cast nephropathy mixed with amyloidosis. These results are consistent with previous studies describing the range of potential histologic findings in patients presenting with renal impairment and an associated monoclonal gammopathy (1,2,12).

The principal limitation of this study relates to its retrospective nature. With this limitation, it was not possible to identify cases where there were minor hemorrhagic complications. Previous work has indicated that a high proportion of patients will acquire a small hematoma after a renal biopsy, whatever the underlying diagnosis (20,25). However, these are unlikely to be of clinical significance, and it can be argued that their detection is unnecessary. Second, although this is the largest series to date to report the incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies, because of the relative rarity of these conditions, the number of patients studied is still relatively small.

Conclusions

This study showed that the risk of a major hemorrhagic complication in patients with a monoclonal gammopathy after a percutaneous renal biopsy is not increased. We suggest that the assessment of renal histology in patients with monoclonal gammopathies remains a valuable diagnostic tool to guide management and help predict clinical outcomes for these.

Disclosures

None.

Acknowledgments

The authors acknowledge the expert opinion given by Professor Michael Sheaff (Royal London Hospital) on a number of the biopsies analyzed in this study.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received January 21, 2010.
  • Accepted June 16, 2010.
  • Copyright © 2010 by the American Society of Nephrology

References

  1. 1.↵
    1. Herrera GA,
    2. Joseph L,
    3. Gu X,
    4. Hough A,
    5. Barlogie B
    : Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128: 875–879, 2004
    OpenUrlPubMed
  2. 2.↵
    1. Montseny JJ,
    2. Kleinknecht D,
    3. Meyrier A,
    4. Vanhille P,
    5. Simon P,
    6. Pruna A,
    7. Eladari D
    : Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13: 1438–1445, 1998
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Torra R,
    2. Blade J,
    3. Cases A,
    4. Lopez-Pedret J,
    5. Montserrat E,
    6. Rozman C,
    7. Revert L
    : Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91: 854–859, 1995
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Falk RH,
    2. Comenzo RL,
    3. Skinner M
    : The systemic amyloidoses. N Engl J Med 337: 898–909, 1997
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lin J,
    2. Markowitz GS,
    3. Valeri AM,
    4. Kambham N,
    5. Sherman WH,
    6. Appel GB,
    7. D'Agati VD
    : Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 12: 1482–1492, 2001
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Paueksakon P,
    2. Revelo MP,
    3. Horn RG,
    4. Shappell S,
    5. Fogo AB
    : Monoclonal gammopathy: Significance and possible causality in renal disease. Am J Kidney Dis 42: 87–95, 2003
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pasquali S,
    2. Casanova S,
    3. Zucchelli A,
    4. Zucchelli P
    : Long-term survival patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 34: 247–254, 1990
    OpenUrlPubMed
  8. 8.↵
    1. Magee CC
    : Kidney biopsy in myeloma. Nephrol Dial Transplant 21: 3601–3602, 2006
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Clark WF,
    2. Stewart AK,
    3. Rock GA,
    4. Sternbach M,
    5. Sutton DM,
    6. Barrett BJ,
    7. Heidenheim AP,
    8. Garg AX,
    9. Churchill DN
    : Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 143: 777–784, 2005
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Eby C
    : Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 145: 151–163, 2009
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Eby C,
    2. Blinder M
    : Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2: 388–394, 2003
    OpenUrlPubMed
  12. 12.↵
    1. Leung N,
    2. Gertz MA,
    3. Zeldenrust SR,
    4. Rajkumar SV,
    5. Dispenzieri A,
    6. Fervenza FC,
    7. Kumar S,
    8. Lacy MQ,
    9. Lust JA,
    10. Greipp PR,
    11. Witzig TE,
    12. Hayman SR,
    13. Russell SJ,
    14. Kyle RA,
    15. Winters JL
    : Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73: 1282–1288, 2008
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ritz E
    : Plasma exchange for acute renal failure of myeloma—Logical, yet ineffective. J Am Soc Nephrol 17: 911–919, 2006
    OpenUrlFREE Full Text
  14. 14.↵
    1. Clark WF,
    2. Garg AX
    : Plasma exchange for myeloma kidney: Cast(s) away? Kidney Int 73: 1211–1213, 2008
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Soares SM,
    2. Fervenza FC,
    3. Lager DJ,
    4. Gertz MA,
    5. Cosio FG,
    6. Leung N
    : Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: Single-center experience in 101 patients. Am J Kidney Dis 52: 1079–1083, 2008
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Levey AS,
    2. Coresh J,
    3. Greene T,
    4. Stevens LA,
    5. Zhang YL,
    6. Hendriksen S,
    7. Kusek JW,
    8. Van Lente F
    : Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Shidham GB,
    2. Siddiqi N,
    3. Beres JA,
    4. Logan B,
    5. Nagaraja HN,
    6. Shidham SG,
    7. Piering WF
    : Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton) 10: 305–310, 2005
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hergesell O,
    2. Felten H,
    3. Andrassy K,
    4. Kuhn K,
    5. Ritz E
    : Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant 13: 975–977, 1998
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Manno C,
    2. Strippoli GF,
    3. Arnesano L,
    4. Bonifati C,
    5. Campobasso N,
    6. Gesualdo L,
    7. Schena FP
    : Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 66: 1570–1577, 2004
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Eiro M,
    2. Katoh T,
    3. Watanabe T
    : Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9: 40–45, 2005
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Song JH,
    2. Cronan JJ
    : Percutaneous biopsy in diffuse renal disease: Comparison of 18- and 14-gauge automated biopsy devices. J Vasc Interv Radiol 9: 651–655, 1998
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Hutchison CA,
    2. Plant T,
    3. Drayson M,
    4. Cockwell P,
    5. Kountouri M,
    6. Basnayake K,
    7. Harding S,
    8. Bradwell AR,
    9. Mead G
    : Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9: 11, 2008
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hutchison CA,
    2. Harding S,
    3. Mead G,
    4. Goehl H,
    5. Storr M,
    6. Bradwell A,
    7. Cockwell
    : Serum free-light chain removal by high cut-off hemodialysis: optimizing removal and supportive care. Artif Organs 32: 910–917
  24. 24.↵
    1. Hutchison CA,
    2. Bradwell AR,
    3. Cook M,
    4. Basnayake K,
    5. Basu S,
    6. Harding S,
    7. Hattersley J,
    8. Evans ND,
    9. Chappel MJ,
    10. Sampson P,
    11. Foggensteiner L,
    12. Adu D,
    13. Cockwell P
    : Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodilaysis. Clin J Am Soc Nephrol 4: 745–754
  25. 25.↵
    1. Waldo B,
    2. Korbet SM,
    3. Freimanis MG,
    4. Lewis EJ
    : The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys. Nephrol Dial Transplant 24: 2433–2439, 2009
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 5, Issue 11
1 Nov 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies
Richard Fish, Jennifer Pinney, Poorva Jain, Clara Addison, Chris Jones, Satish Jayawardene, John Booth, Alexander J. Howie, Tareck Ghonemy, Shahista Rajabali, David Roberts, Lucy White, Sofia Khan, Matthew Morgan, Paul Cockwell, Colin A. Hutchison
CJASN Nov 2010, 5 (11) 1977-1980; DOI: 10.2215/CJN.00650110

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies
Richard Fish, Jennifer Pinney, Poorva Jain, Clara Addison, Chris Jones, Satish Jayawardene, John Booth, Alexander J. Howie, Tareck Ghonemy, Shahista Rajabali, David Roberts, Lucy White, Sofia Khan, Matthew Morgan, Paul Cockwell, Colin A. Hutchison
CJASN Nov 2010, 5 (11) 1977-1980; DOI: 10.2215/CJN.00650110
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Acute Kidney Injury among Black Patients with Sickle Cell Trait and Sickle Cell Disease
  • Acute Kidney Injury, Microvascular Rarefaction, and Estimated Glomerular Filtration Rate in Kidney Transplant Recipients
  • The Association of Time to Organ Procurement on Short- and Long-Term Outcomes in Kidney Transplantation
Show more Original Articles

Clinical Nephrology

  • Acute Kidney Injury among Black Patients with Sickle Cell Trait and Sickle Cell Disease
  • Acute Kidney Injury, Microvascular Rarefaction, and Estimated Glomerular Filtration Rate in Kidney Transplant Recipients
  • The Association of Time to Organ Procurement on Short- and Long-Term Outcomes in Kidney Transplantation
Show more Clinical Nephrology

Cited By...

  • Pathophysiology and management of monoclonal gammopathy of renal significance
  • Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance
  • Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy
  • The Native Kidney Biopsy: Update and Evidence for Best Practice
  • Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases
  • Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire